Scientists found a special group of genes in bacteria. These genes make a team of medicines to kill other bacteria.

科學家在細菌中發現了一組特殊的基因。這些基因能產生一組藥物來殺死其他細菌。

In the past, scientists looked for one medicine at a time. Now, they found a big group of four medicines. These medicines work together. They stop the bacteria from using biotin. Biotin is a vitamin that bacteria need to live.

過去，科學家一次只尋找一種藥物。現在，他們發現了一個由四種藥物組成的大群組。這些藥物會協同工作，阻止細菌使用生物素。生物素是細菌生存所需的一種維生素。

The scientists tested these medicines in a lab. They used a mouse with a bad infection. The team of medicines worked better than one medicine alone. It killed bacteria that other drugs cannot kill.

科學家在實驗室中測試了這些藥物。他們使用了一隻患有嚴重感染的小鼠。這組藥物的效果比單一藥物更好，能夠殺死其他藥物無法殺死的細菌。

Many types of these bacteria have the same genes. This means nature made this team of medicines a long time ago. This helps the medicines work better and stops bacteria from fighting back.

許多類型的這類細菌具有相同的基因。這意味著大自然在很久以前就製造了這組藥物。這有助於提高藥效，並防止細菌產生抗藥性。

This discovery helps scientists make new medicines. These medicines can fight very strong bacteria.

這項發現有助於科學家開發新藥，可用於對抗非常強大的細菌。

Researchers have found a shared genetic 'megacluster' in Streptomyces bacteria. This cluster produces a group of antibiotics that work together to attack the way bacteria produce biotin, an essential vitamin.

研究人員在鏈黴菌中發現了一個共有的基因「巨簇」。這個基因簇會產生一組抗生素，共同作用以攻擊細菌產生生物素（一種必需維生素）的方式。

In the past, scientists usually looked for single active molecules to create antibiotics. However, recent evidence shows that some bacteria use coordinated systems of multiple molecules. In this study, researchers identified a megacluster in Streptomyces that produces four different antibiotic families and a protein called streptavidin. Together, these components stop bacterial growth by blocking enzymes and trapping biotin, which the bacteria need to survive.

過去，科學家通常尋找單一活性分子來研發抗生素。然而，最近的證據顯示，某些細菌使用由多個分子組成的協調系統。在本次研究中，研究人員在鏈黴菌中鑑定出一個巨簇，能產生四個不同的抗生素家族以及一種稱為鏈黴親和蛋白的蛋白質。這些成分共同作用，透過阻斷酵素並捕捉細菌生存必需的生物素，來停止細菌生長。

This discovery is important because it suggests that we should study these natural combinations rather than just single compounds. The researchers tested this genetic structure in laboratory strains and found that the resulting metabolites are very effective against Gram-negative and mycobacterial species. Furthermore, a combination of two specific compounds showed strong results in treating drug-resistant E. coli in mice. Because this genetic structure is found in many different species, it suggests that nature has optimized this system to prevent bacteria from developing resistance.

這項發現至關重要，因為它表明我們應該研究這些天然組合，而非僅僅研究單一化合物。研究人員在實驗室菌株中測試了此基因結構，發現其產生的代謝產物對革蘭氏陰性菌和分枝桿菌屬非常有效。此外，兩種特定化合物的組合在治療小鼠體內的耐藥大腸桿菌時顯示出強大的效果。由於這種基因結構存在於許多不同物種中，這表明自然界已優化此系統，以防止細菌產生耐藥性。

The discovery of this megacluster provides a useful model for creating combination therapies that target essential metabolic processes to fight drug-resistant bacteria.

這個巨簇的發現提供了一個有用的模型，可用於創建針對必需代謝過程的組合療法，以對抗耐藥細菌。

Researchers have identified a genetically conserved megacluster in Streptomyces bacteria that produces a synergistic suite of antibiotics targeting the biotin biosynthetic pathway.

研究人員在鏈黴菌中發現一個基因保守的巨簇，能產生一套協同作用的抗生素，針對生物素的生物合成路徑。

Historically, the identification of natural product antibiotics has focused on the isolation of individual bioactive molecules from biosynthetic gene clusters. However, recent evidence suggests the existence of coordinated multi-metabolite systems. In the present study, a biosynthetic megacluster was identified within Streptomyces spp. that encodes four distinct natural product families—stravidins, acidomycin, dapamycins, and 2-methyl-7-keto-8-aminopelargonic acid (α-Me-KAPA)—alongside the biotin-binding protein streptavidin. These components collectively disrupt bacterial biotin metabolism via a multifaceted approach involving enzyme inhibition, cofactor mimicry, prodrug activation, and biotin sequestration.

在過去，鑑定天然產物抗生素主要集中於從生物合成基因簇中分離單一的生物活性分子。然而，最近的證據顯示存在協調的多代謝產物系統。在本研究中，於鏈黴菌屬（Streptomyces spp.）中鑑定出一個生物合成巨簇，其編碼四個不同的天然產物家族——stravidins、acidomycin、dapamycins 及 2-甲基-7-酮-8-氨基庚酸 (α-Me-KAPA)——以及生物素結合蛋白 streptavidin。這些成分透過一種多方面的方法，包括酵素抑制、輔因子模擬、前藥活化及生物素截留，共同破壞細菌的生物素代謝。

The institutional positioning of this discovery emphasizes a shift toward reconstructing native synergistic systems rather than isolating single compounds. The megacluster's architecture, comprising 65,808 base pairs, was validated through heterologous expression in lab strains of Streptomyces. The resulting metabolites demonstrate synergistic efficacy against Gram-negative and mycobacterial species. Specifically, a combination of stravidin S2 and α-Me-KAPA exhibited enhanced therapeutic efficacy in a murine model of multidrug-resistant Escherichia coli infection. The conservation of this genetic architecture across multiple Streptomyces species suggests an evolutionary optimization for the suppression of conserved metabolic pathways, which potentially complicates the development of bacterial resistance.

此發現的體制定位強調了研究重心正轉向重建原生的協同系統，而非僅分離單一化合物。該巨簇的結構包含 65,808 個鹼基對，已透過在鏈黴菌實驗室菌株中的異源表達得到驗證。所得的代謝產物對革蘭氏陰性菌及分枝桿菌屬展現出協同療效。具體而言，stravidin S2 與 α-Me-KAPA 的組合在多重耐藥大腸桿菌感染的小鼠模型中展現出增強的治療效果。此基因結構在多個鏈黴菌物種中的保守性，顯示其為抑制保守代謝路徑而進行的演化優化，這可能會增加開發細菌耐藥性的難度。

The discovery of this megacluster provides a template for developing combination therapies that target essential metabolic processes to combat multidrug-resistant pathogens.

發現此巨簇為開發針對必需代謝過程的組合療法提供了一個模板，可用於對抗多重耐藥病原體。